CA
NZ
UK
AU
IND
US
Citigroup Global Markets Holdings Inc. filed a preliminary pricing supplement (Form 424B2) on August 4, 2026, for Autocallable Buffered Notes linked to the MSCI Emerging Markets Index, with an expected maturity in August 2028 and a stated principal amount of $1,000 per security.
Citigroup Global Markets Holdings Inc. filed a preliminary pricing supplement on August 4, 2026, for Autocallable Barrier Securities linked to the worst performing of the Nasdaq-100 Index and the State Street SPDR S&P 500 ETF Trust, with a stated maturity of August 12, 2031.
IREN Limited filed a prospectus supplement on August 4, 2026, registering up to 11,981,668 ordinary shares for resale by selling shareholders who received those shares in connection with the company's merger with Mirantis, Inc., which closed on August 3, 2026.
IREN Limited (NASDAQ: IREN) filed a Form 8-K on August 4, 2026, disclosing the closing of its acquisition of Mirantis, Inc. and the filing of a prospectus supplement covering the resale of up to 11,981,668 ordinary shares by certain selling shareholders.
Albany International Corp. (NYSE: AIN) filed a Form 8-K on August 4, 2026, reporting its second-quarter 2026 operating results for the period ended June 30, 2026, along with third-quarter guidance.
SharonAI Holdings Inc. filed a Form 8-K with the SEC on August 4, 2026, disclosing a press release announcing a US$373 million Five-Year AI Cloud Service Agreement.
A Form 4 filed with the SEC on August 4, 2026 reports that Richard E. Uihlein, a director and 10% owner of Galectin Therapeutics Inc. (NASDAQ: GALT), converted two series of Line of Credit Convertible Notes into common stock on July 31, 2026, through …
Ball Corporation filed a Current Report on Form 8-K with the SEC on August 4, 2026, disclosing that it issued a press release and would hold a conference call regarding its financial results for the quarter ended June 30, 2026.
Rhythm Pharmaceuticals, Inc. filed a Current Report on Form 8-K on August 4, 2026, disclosing preliminary Phase 2 trial data for RM-718 in patients with acquired hypothalamic obesity and announcing its financial results for the second quarter ended June 30, 2026.
RE/MAX Holdings, Inc. and The Real Brokerage Inc. jointly filed a Rule 425 notice on August 4, 2026, reminding holders of RE/MAX Class A Common Stock of an August 18, 2026 deadline to elect the form of merger consideration they wish to receive in …
Please wait processing your request...